This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: May 27, 2009
Last updated: August 17, 2016
Last verified: May 2013
This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the outpatient setting.

Condition Intervention Phase
Sickle Cell Disease Drug: GMI-1070 Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/Phase 2 Study of the Safety, Pharmacokinetics, and Microvascular Effect of Titrating Doses of Intravenous GMI-1070, a Pan-Selectin Inhibitor, in Adults With Sickle Cell Disease

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Safety as Measured by the Number of Participants With Adverse Events [ Time Frame: 28 days ]

Secondary Outcome Measures:
  • Total Plasma Clearance [ Time Frame: 48 hours ]
  • Volume of the Central Compartment [ Time Frame: 48 hours ]
  • Intercompartmental Clearance [ Time Frame: 48 hours ]
  • Volume of the Peripheral Compartment [ Time Frame: 48 hours ]

Other Outcome Measures:
  • Blood Flow and Biomarkers of Adhesion [ Time Frame: 48 hours ]
    As an exploratory outcome mean change in microvascular blood flow from baseline to each time point was measured. Microvascular blood flow was also measured as microFI, perfused vessel density, and RBC velocity.

Enrollment: 15
Study Start Date: May 2009
Study Completion Date: September 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GMI-1070 Drug: GMI-1070
Intravenous GMI-1070 given as two doses over the course of one day


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 to 45 years
  • Established diagnosis of SCD-SS or SCD-SB0-thal
  • At medical baseline, with no evidence of worsening of disease over the last 3 months
  • Available and agree to return for follow-up visits for the full duration of the study
  • Able to cooperate with study procedures
  • Documented and observed written informed consent

Exclusion Criteria:

  • Vaso-occlusive crisis
  • Recent major surgery, hospitalization, infection, significant bleeding, cerebrovascular accident or seizure, or transfusion
  • Currently receiving, or has received within the previous 4 weeks, any other investigational agent
  • Pregnant or lactating female; or female of childbearing age unable or unwilling to comply with birth control or abstinence during the course of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00911495

United States, California
Children's Hospital & Research Center Oakland
Oakland, California, United States, 94609
University of California at Davis, CCRC
Sacramento, California, United States, 95817
United States, North Carolina
Duke Comprehensive Sickle Cell Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Study Director: Helen Thackray, MD GlycoMimetics Incorporated
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Pfizer Identifier: NCT00911495     History of Changes
Other Study ID Numbers: GMI-1070-103
Study First Received: May 27, 2009
Results First Received: September 11, 2012
Last Updated: August 17, 2016

Keywords provided by Pfizer:
Sickle Cell Disease

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on September 20, 2017